Immunohistochemistry of Complement Response on Human Renal Cell Carcinoma Biopsies
Overview
Authors
Affiliations
The goal of the study was to characterize the complement humoral and cellular antitumor responses on primary renal cell carcinoma biopsies. As an original observation, complement activation was found on 11/22 cases. Classical complement pathway activation was characterized by tumor C1q complement protein and IgG deposition (5/22 cases). Alternative or nonimmune complement pathway activation was seen as tissue deposition of C3 (6/22 cases). The membrane attack complex was present in cases with alternative complement pathway activation at the sites of tumor necrosis. Renal cell carcinomas with complement activation overexpressed at least one of the complement regulatory factors (membrane cofactor protein, decay accelerating factor, membrane attack complex inhibitor) and major histocompatibility complex class II molecules. Tumor infiltrating lymphocytes were present in most of the renal cell carcinomas with complement activation (8/11). However, the number of tumor-infiltrating lymphocytes was correlated with the intensity of major histo-compatibility complex-II expression in 18/22 cases. Detection of complement activation and immune cell infiltrates on renal cell carcinoma primary biopsies may serve as a new predictive factor for immunotherapy.
Wu Y, Terekhanova N, Caravan W, Naser Al Deen N, Lal P, Chen S Nat Commun. 2023; 14(1):1681.
PMID: 36973268 PMC: 10042888. DOI: 10.1038/s41467-023-37211-7.
Role of Complement in Regulating Inflammation Processes in Renal and Prostate Cancers.
Netti G, Franzin R, Stasi A, Spadaccino F, Dello Strologo A, Infante B Cells. 2021; 10(9).
PMID: 34572075 PMC: 8471315. DOI: 10.3390/cells10092426.
Deposition of the Membrane Attack Complex in Healthy and Diseased Human Kidneys.
Koopman J, van Essen M, Rennke H, de Vries A, van Kooten C Front Immunol. 2021; 11:599974.
PMID: 33643288 PMC: 7906018. DOI: 10.3389/fimmu.2020.599974.
Immune consequences of anti-angiogenic therapyin renal cell carcinoma.
Brodaczewska K, Szczylik C, Kieda C Contemp Oncol (Pozn). 2018; 22(1A):14-22.
PMID: 29628789 PMC: 5885083. DOI: 10.5114/wo.2018.73878.
Elevated expression of SLC34A2 inhibits the viability and invasion of A549 cells.
Yang W, Wang Y, Pu Q, Ye S, Ma Q, Ren J Mol Med Rep. 2014; 10(3):1205-14.
PMID: 25017204 PMC: 4121420. DOI: 10.3892/mmr.2014.2376.